Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 16/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428179 | 0.78 | TRPV1 (0.36) | TRPV1 | |
| SCHEMBL427922 | 0.76 | LMNA (0.50) | TRPV1MAPK1 | |
| SCHEMBL432662 | 0.74 | TRPV1 (0.51) | TRPV1MAPK1 | |
| SCHEMBL431283 | 0.74 | HPGD (0.39) | TRPV1 | |
| SCHEMBL430194 | 0.74 | TRPV1 (0.42) | TRPV1 | |
| SCHEMBL432661 | 0.74 | TRPV1 (0.51) | TRPV1MAPK1 | |
| SCHEMBL433133 | 0.74 | TRPV1 (0.51) | TRPV1MAPK1 | |
| SCHEMBL427940 | 0.74 | TRPV1 (0.40) | TRPV1 | |
| SCHEMBL433270 | 0.73 | MTNR1A (0.52) | TRPV1 | |
| SCHEMBL1964461 | 0.73 | TRPV1 (0.33) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885704-B1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LAB (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110144057-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | US | disclosed |
| US-7902236-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | ABBOTT LABORATORIES (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100010055-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF | ABBOTT LABORATORIES (US) | 2010-01-14 | — | — | US | disclosed |
| US-7504520-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| US-20060281799-A1 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | ABBVIE INC. | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281799-A1 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | TRPV1, TMEM109, CACNA1E | TRPV1 1/4885MAPK1 1424/4885TRPM8 97/4885 |
| US-20110144057-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF | TRPV1, TMEM109, CACNA1E | TRPV1 1/4885MAPK1 1424/4885TRPM8 97/4885 |
| US-20100010055-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF | TRPV1, TMEM109, CACNA1E | TRPV1 1/4885MAPK1 1424/4885TRPM8 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.